Significance of the TGF-β1/il-6 axis in oral cancer

Miao Fen Chen, Wen Hung Wang, Paul Yang Lin, Kuan Der Lee, Wen Cheng Chen

研究成果: 雜誌貢獻文章

22 引文 (Scopus)

摘要

The aim of the present study was to explore specific molecular markers that could lead to new insights into the identification of innovative treatments in oral cancer. The role of TGF-β1 (transforming growth factor-β1) and its predictive power in the prognosis of oral cancer has been identified. Human oral cancer cell lines, including SCC4 and SCC25, were selected for cellular experiments. Changes in tumour aggressiveness, responses to treatment and the signalling pathway responsible were investigated in vitro. Furthermore, 125 oral cancer tissue specimens were constructed into tissue microarray blocks for immunohistochemical analysis to correlate the expression of TGF-β1 with clinical outcome. Using in vitro experiments, our results revealed that activated TGF-β1 signalling resulted in more aggressive tumour growth, augmented the epithelial- mesenchymal transition and more resistance to treatment. Activated IL-6 (interleukin-6) signalling could be the mechanism underlying the effects of TGF-β1 on oral cancer. Regarding clinical data, the incidence of TGF-β1 immunoreactivity in oral cancer specimens was significantly higher than in non-malignant epithelium and positively linked to IL-6 staining. Furthermore, expression of TGF-β1 was significantly correlated with the risk of lymph node involvement, disease recurrence and shorter survival in patients with pathological stage III-IV oral cancer. In conclusion, the TGF-β1/IL-6 axis had predictive power in the prognosis of oral cancer, and targeting TGF-β1 could represent a promising treatment strategy.
原文英語
頁(從 - 到)459-472
頁數14
期刊Clinical Science
122
發行號10
DOIs
出版狀態已發佈 - 五月 2012
對外發佈Yes

指紋

Mouth Neoplasms
Transforming Growth Factors
Interleukin-6
Epithelial-Mesenchymal Transition
Therapeutics
Neoplasms
Epithelium
Lymph Nodes
Staining and Labeling
Recurrence
Cell Line
Survival
Incidence
Growth

ASJC Scopus subject areas

  • Medicine(all)

引用此文

Chen, M. F., Wang, W. H., Lin, P. Y., Lee, K. D., & Chen, W. C. (2012). Significance of the TGF-β1/il-6 axis in oral cancer. Clinical Science, 122(10), 459-472. https://doi.org/10.1042/CS20110434

Significance of the TGF-β1/il-6 axis in oral cancer. / Chen, Miao Fen; Wang, Wen Hung; Lin, Paul Yang; Lee, Kuan Der; Chen, Wen Cheng.

於: Clinical Science, 卷 122, 編號 10, 05.2012, p. 459-472.

研究成果: 雜誌貢獻文章

Chen, MF, Wang, WH, Lin, PY, Lee, KD & Chen, WC 2012, 'Significance of the TGF-β1/il-6 axis in oral cancer', Clinical Science, 卷 122, 編號 10, 頁 459-472. https://doi.org/10.1042/CS20110434
Chen, Miao Fen ; Wang, Wen Hung ; Lin, Paul Yang ; Lee, Kuan Der ; Chen, Wen Cheng. / Significance of the TGF-β1/il-6 axis in oral cancer. 於: Clinical Science. 2012 ; 卷 122, 編號 10. 頁 459-472.
@article{0a7237365c084abe9d50c897a2013ebb,
title = "Significance of the TGF-β1/il-6 axis in oral cancer",
abstract = "The aim of the present study was to explore specific molecular markers that could lead to new insights into the identification of innovative treatments in oral cancer. The role of TGF-β1 (transforming growth factor-β1) and its predictive power in the prognosis of oral cancer has been identified. Human oral cancer cell lines, including SCC4 and SCC25, were selected for cellular experiments. Changes in tumour aggressiveness, responses to treatment and the signalling pathway responsible were investigated in vitro. Furthermore, 125 oral cancer tissue specimens were constructed into tissue microarray blocks for immunohistochemical analysis to correlate the expression of TGF-β1 with clinical outcome. Using in vitro experiments, our results revealed that activated TGF-β1 signalling resulted in more aggressive tumour growth, augmented the epithelial- mesenchymal transition and more resistance to treatment. Activated IL-6 (interleukin-6) signalling could be the mechanism underlying the effects of TGF-β1 on oral cancer. Regarding clinical data, the incidence of TGF-β1 immunoreactivity in oral cancer specimens was significantly higher than in non-malignant epithelium and positively linked to IL-6 staining. Furthermore, expression of TGF-β1 was significantly correlated with the risk of lymph node involvement, disease recurrence and shorter survival in patients with pathological stage III-IV oral cancer. In conclusion, the TGF-β1/IL-6 axis had predictive power in the prognosis of oral cancer, and targeting TGF-β1 could represent a promising treatment strategy.",
keywords = "Epithelial-mesenchymal transition, Head and neck squamous cell carcinoma, Interleukin-6 (IL-6), Oral cancer, Transforming growth factor-β1 (TGF-β1)",
author = "Chen, {Miao Fen} and Wang, {Wen Hung} and Lin, {Paul Yang} and Lee, {Kuan Der} and Chen, {Wen Cheng}",
year = "2012",
month = "5",
doi = "10.1042/CS20110434",
language = "English",
volume = "122",
pages = "459--472",
journal = "Clinical Science",
issn = "0143-5221",
publisher = "Portland Press Ltd.",
number = "10",

}

TY - JOUR

T1 - Significance of the TGF-β1/il-6 axis in oral cancer

AU - Chen, Miao Fen

AU - Wang, Wen Hung

AU - Lin, Paul Yang

AU - Lee, Kuan Der

AU - Chen, Wen Cheng

PY - 2012/5

Y1 - 2012/5

N2 - The aim of the present study was to explore specific molecular markers that could lead to new insights into the identification of innovative treatments in oral cancer. The role of TGF-β1 (transforming growth factor-β1) and its predictive power in the prognosis of oral cancer has been identified. Human oral cancer cell lines, including SCC4 and SCC25, were selected for cellular experiments. Changes in tumour aggressiveness, responses to treatment and the signalling pathway responsible were investigated in vitro. Furthermore, 125 oral cancer tissue specimens were constructed into tissue microarray blocks for immunohistochemical analysis to correlate the expression of TGF-β1 with clinical outcome. Using in vitro experiments, our results revealed that activated TGF-β1 signalling resulted in more aggressive tumour growth, augmented the epithelial- mesenchymal transition and more resistance to treatment. Activated IL-6 (interleukin-6) signalling could be the mechanism underlying the effects of TGF-β1 on oral cancer. Regarding clinical data, the incidence of TGF-β1 immunoreactivity in oral cancer specimens was significantly higher than in non-malignant epithelium and positively linked to IL-6 staining. Furthermore, expression of TGF-β1 was significantly correlated with the risk of lymph node involvement, disease recurrence and shorter survival in patients with pathological stage III-IV oral cancer. In conclusion, the TGF-β1/IL-6 axis had predictive power in the prognosis of oral cancer, and targeting TGF-β1 could represent a promising treatment strategy.

AB - The aim of the present study was to explore specific molecular markers that could lead to new insights into the identification of innovative treatments in oral cancer. The role of TGF-β1 (transforming growth factor-β1) and its predictive power in the prognosis of oral cancer has been identified. Human oral cancer cell lines, including SCC4 and SCC25, were selected for cellular experiments. Changes in tumour aggressiveness, responses to treatment and the signalling pathway responsible were investigated in vitro. Furthermore, 125 oral cancer tissue specimens were constructed into tissue microarray blocks for immunohistochemical analysis to correlate the expression of TGF-β1 with clinical outcome. Using in vitro experiments, our results revealed that activated TGF-β1 signalling resulted in more aggressive tumour growth, augmented the epithelial- mesenchymal transition and more resistance to treatment. Activated IL-6 (interleukin-6) signalling could be the mechanism underlying the effects of TGF-β1 on oral cancer. Regarding clinical data, the incidence of TGF-β1 immunoreactivity in oral cancer specimens was significantly higher than in non-malignant epithelium and positively linked to IL-6 staining. Furthermore, expression of TGF-β1 was significantly correlated with the risk of lymph node involvement, disease recurrence and shorter survival in patients with pathological stage III-IV oral cancer. In conclusion, the TGF-β1/IL-6 axis had predictive power in the prognosis of oral cancer, and targeting TGF-β1 could represent a promising treatment strategy.

KW - Epithelial-mesenchymal transition

KW - Head and neck squamous cell carcinoma

KW - Interleukin-6 (IL-6)

KW - Oral cancer

KW - Transforming growth factor-β1 (TGF-β1)

UR - http://www.scopus.com/inward/record.url?scp=84863385960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863385960&partnerID=8YFLogxK

U2 - 10.1042/CS20110434

DO - 10.1042/CS20110434

M3 - Article

C2 - 22103462

AN - SCOPUS:84863385960

VL - 122

SP - 459

EP - 472

JO - Clinical Science

JF - Clinical Science

SN - 0143-5221

IS - 10

ER -